MedTrace Logo

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00742391 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2015-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.

Conditions

  • Actinic Keratoses

Interventions

DRUG

PEP005 (ingenol mebutate) Gel

two day treatment

DRUG

Vehicle gel

two day treatment

Sponsors & Collaborators

  • Peplin

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00742391 on ClinicalTrials.gov